ema prac naion semaglutide The use of medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION) EMA warns Ozempic linked to – Semaglutide may cause blindness—US study

Chips are typically high in refined fats, which slow down digestion and can cause significant bloating or discomfort for those on GLP-1s

There is ongoing research into potential off-label uses for various metabolic conditions, broadening its applicability

These include: modulating key inflammatory pathways decreasing mucosal blood flow causing bowel dysfunction in different ways activating the fight or flight response in the central nervous system which can slow down or even stop the digestive process altering the gut flora, and increasing intestinal permeability

Why real-world escalation often takes longer In clinical trials, escalation timelines are fixed

Obesity is a common factor that can lead to high blood pressure